Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Pittsburgh, USA-based Viatris, which was formed in 2020 through the merger of Mylan and Pfizer's, saw its shares fall 4.2% to ...

Leerink Partnrs has trimmed its Q2 2025 earnings estimate for Merck & Co., Inc., foreseeing a dip to $1.96 per share from ...

Gold Spot US Dollar, Intel Corporation, Microsoft Corporation, Cisco Systems Inc. Read 's Market Analysis on Investing.com UK.